This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.
Amgen submits melanoma and cholesterol drugs to EMA. Regulator will assess talimogene laherparepvec and evolocumab. ... One of the drugs is talimogene laherparepvec, an oncology treatment that Amgen has submitted for use in the treatment of adults with
Phase III data for Amgen's cancer-killing virus product talimogene laherparepvec ( T-VEC) back what could be a potential advance in the treatment of melanoma.
The melanoma immunotherapeutic - talimogene laherparepvec ( also known as OncoVex) - works by introducing a virus that selectively replicates in tumour cells, causing them to rupture. ... All told, 16 per cent of patients treated with talimogene
The most advanced is Amgen's OncoVex ( talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer melanoma.
The early application comes shortly after Amgen filed marketing applications for metastatic melanoma immunotherapy talimogene laherparepvec and PCSK9 inhibitor evolocumab for high cholesterol in both the US and Europe. ... Analysts at JP Morgan have
trials with Amgen's talimogene laherparepvec in melanoma, as well as Incyte's INCB24360, an indoleamine 2, 3-dioxygenase inhibitor, in NSCLC.